ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%

Zhitong
2025.10.20 23:50

ANKE BIO announced that at the 2025 European Society for Medical Oncology Annual Meeting, the company presented the latest research results of its self-developed biological innovative drug HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma in the Ib/II phase dose escalation and expansion study. As of February 20, 2025, this study has enrolled 60 HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma first-line patients. According to the assessment by an independent imaging evaluation committee, the objective response rate of the HuA21 group was 80.8%, while the objective response rate of the trastuzumab group was 76.7%, demonstrating good anti-tumor activity. There were no statistically significant differences in the demographic data and baseline characteristics between the two groups of patients

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer